SC 13G/A 1 tv513512_sc13ga.htm SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO

FILED PURSUANT TO RULE 13d-2

 

(Amendment No. 2)*

 

Acasti Pharma Inc.

 

(Name of Issuer)

 

Common Shares

 

(Title of Class of Securities)

 

00430K105

 

(CUSIP Number)

 

December 31, 2018

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨   Rule 13d-1(b)
x  Rule 13d-1(c)
¨   Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 00430K105

13G Page 2 of 6

 

1.   NAMES OF REPORTING PERSONS

George W. Haywood
 
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨
 
3.   SEC USE ONLY
 
 
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
 

NUMBER OF SHARES BENEFICIALLY

OWNED BY EACH REPORTING PERSON WITH

5.   SOLE VOTING POWER
 
6,716,906 (1)
6.   SHARED VOTING POWER
 
680,000 (2)
7.   SOLE DISPOSITIVE POWER
 
6,716,906 (1)
8.   SHARED DISPOSITIVE POWER
 
680,000 (2)

9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,396,906
 
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
 
11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.2%
 
12.   TYPE OF REPORTING PERSON (see instructions)

IN

 

 

 

(1)Includes 2,291,162 shares underlying warrants.

 

(2)Represents 680,000 shares owned jointly by Mr. Haywood and his non-minor children.

 

 

CUSIP No. 00430K105

13G Page 3 of 6

 

Item 1.

 

  (a) Name of Issuer
Acasti Pharma Inc.
     
  (b) Address of Issuer’s Principal Executive Offices
545 Promenade du Centropolis, Suite 100, Laval, Quebec, Canada H7T 0A3

 

Item 2.

 

  (a) Name of Person Filing
George W. Haywood
     
  (b) Address of the Principal Office or, if None, Residence
c/o Moomjian, Waite & Coleman, LLP, 100 Jericho Quadrangle, Suite 208, Jericho, New York 11753
     
  (c) Citizenship
United States
     
  (d) Title of Class of Securities
Common Shares
     
  (e) CUSIP Number
00430K105

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a)  ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b)  ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c)  ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d)  ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e)  ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f)  ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g)  ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h)  ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j)  ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
       
  (k)  ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 

CUSIP No. 00430K105

13G Page 4 of 6

 

Item 4.  Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

 

           
         
         
  (a)   Amount beneficially owned:   7,396,906
           
  (b)   Percent of class:   9.2%
           
  (c)   Number of shares as to which the person has:    
           
      (i) Sole power to vote or to direct the vote: 6,716,906
           
      (ii) Shared power to vote or to direct the vote: 680,000
           
      (iii) Sole power to dispose or to direct the disposition of: 6,716,906
           
      (iv) Shared power to dispose or to direct the disposition of: 680,000

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Included as shares for which there exist sole voting and dispositive power are 2,291,162 shares underlying warrants.

 

Included as shares for which there exists shared voting and dispositive power are an aggregate of 680,000 shares owned jointly by Mr. Haywood and his non-minor children, which children would have the shared right to the receipt of dividends from, and proceeds for the sale of, such shares.

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

 Not applicable.

 

 

CUSIP No. 00430K105

13G Page 5 of 6

 

Item 8.  Identification and Classification of Members of the Group.

 

 Not applicable.

 

Item 9.  Notice of Dissolution of Group.

 

 Not applicable.

 

Item 10.  Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.  

 

 

CUSIP No. 00430K105

13G Page 6 of 6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

     
 

February 13, 2019

 
  Date  
     
 

/s/ George W. Haywood

 
  Signature  
     
 

George W. Haywood

 
  Name/Title